Advertisement

Use of Methadone in Opioid Maintenance Treatment

Chapter

Abstract

Many studies have repeatedly shown that the daily administration of methadone decreases morbidity and mortality in patients with an addiction to opioids and related substances. First established in the 1960s, methadone programs soon become an essential component for the treatment of this patient population. In addition to the dispensing of methadone, the program provides medical and counseling services that are active components of the treatment plan. The legal aspects that regulate the MMT programs and the unique pharmacokinetics and pharmacodynamics of methadone require special attention.

Keywords

Illicit Drug Trough Level Methadone Dose Necrotizing Fasciitis Methadone Maintenance Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Effective medical treatment of opiate addiction. NIH Consensus Statement Online 17–19 Nov 1997 [cited 17 March 2012].Google Scholar
  2. 2.
    Dole VP, Nyswander ME. Methadone maintenance: a ten year perspective. JAMA. 1976;193:646–50.CrossRefGoogle Scholar
  3. 3.
    Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcomes. New York: Springer; 1991.CrossRefGoogle Scholar
  4. 4.
    D’Aunno T, Pollack H. Changes in methadone treatment practices. JAMA. 2002;288(7):850–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Blaney T, Craig R. Methadone maintenance: does dose determine differences in outcomes. J Subst Abuse Treat. 1999;16(3):221–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National survey of substance abuse treatment services (N-SSATS); 2007.Google Scholar
  7. 7.
    Maremmani I, Barra M, Bignamini E, et al. Clinical foundations for the use of methadone. Italian consensus panel on methadone treatment. Heroin Addict Relat Clin Probl. 2002;4(2):19–32.Google Scholar
  8. 8.
    Maremmani I, Pacini M, Lubrano S, Lovrecic M. When “enough” is still not “enough”: effectiveness of high-dose methadone in the treatment of heroin addiction. Heroin Addict Relat Clin Probl. 2003;5(1):17–32.Google Scholar
  9. 9.
    Schoenbaum E, Hartel D, Selwyn P. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989;321:874–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Ward J, Hall W, Mattick R. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Metzger D, Woody G, McLellan T, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049–56.PubMedGoogle Scholar
  12. 12.
    Institute of Medicine. No time to lose: making the most of HIV prevention. Washington, DC: National Academy Press; 2000.Google Scholar
  13. 13.
    Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med. 2000;67:423–8.PubMedGoogle Scholar
  14. 14.
    Pollack HA. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med Decis Making. 2001;21:357–67.PubMedGoogle Scholar
  15. 15.
    Gronbladh L, Ohland M, Gunne L. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82:874–9.CrossRefGoogle Scholar
  16. 16.
    Marsch L. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour and criminality: a meta-analysis. Addiction. 1998;93:515–32.PubMedCrossRefGoogle Scholar
  17. 17.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author; 2000.Google Scholar
  18. 18.
    Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale. J Psychoactive Drugs. 2003;35(2):253–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Code of Federal Regulations 42 CFR  chapter 1, part 8.12 (i) (2) (i)–(viii).
  20. 20.
    Benet L, Kroetz D, Sheiner L. Pharmokinetics. In: Hardman J, Limbird L, editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 3–27.Google Scholar
  21. 21.
    Stine SM, Greenwald MK, Kosten TR. Pharmacologic therapies for opioid addiction. In: Graham AW et al., editors. Principles of addiction medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003. p. 735–50.Google Scholar
  22. 22.
    Strang J, McCmbridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ. 2003;326:959–60.PubMedCrossRefGoogle Scholar
  23. 23.
    California Society of Addiction Medicine (CSAM). Guidelines for physicians working in California Opioid Treatment Programs; 2009.Google Scholar
  24. 24.
    Craig RJ. Effectiveness of low dose methadone maintenance treatment for the treatment of inner city heroin addicts. Int J Addict. 1980;15:701–10.PubMedGoogle Scholar
  25. 25.
    Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow up results from the National Treatment Outcomes Research Study. Drug Alcohol Depend. 2001;62:255–64.PubMedCrossRefGoogle Scholar
  26. 26.
    Tenore PL. Guidance on optimal methadone dosing. Addict Treat Forum. 2003;12(3):1, 6–7.Google Scholar
  27. 27.
    Loimer N, Schmid R. The use of plasma levels to optimise methadone maintenance treatment. Drug Alcohol Depend. 1992;30(3):241–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi AA, Bochner F, et al. Subjective and physiological responses among racemic–methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Br J Clin Pharmacol. 2004;58:609–17.PubMedCrossRefGoogle Scholar
  29. 29.
    Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. JAMA. 1973;223:665–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Novick DM, Richman BL, Friedman JM, et al. The medical status of methadone maintained patients in treatment for 11–18 years. Drug Alcohol Depend. 1993;33:235–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Leavitt S. Methadone-drug interactions. Addict Treat Forum. Nov 2005.Google Scholar
  32. 32.
    Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet. 2000;356(9247):2069–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Faragon JJ, Piliero P. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. 2003;13(9):433–50.PubMedGoogle Scholar
  34. 34.
    Byrne A. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med. 2009;151(3):216.PubMedCrossRefGoogle Scholar
  35. 35.
    Cohen SP, Mao J. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med. 2009;151(3):216.PubMedCrossRefGoogle Scholar
  36. 36.
    Girgis G. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med. 2009;151(3):216.CrossRefGoogle Scholar
  37. 37.
    Bart G. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med. 2009;151(3):216.CrossRefGoogle Scholar
  38. 38.
    Gourevitch M. First, do no harm… reduction? Ann Intern Med. 2009;150:417–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Carpentier PJ, Krabbe PF, van Gagh MT, Knapen LJ, Buitelaar JK, de Jong CA. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict. 2009;18(6):470–80.PubMedCrossRefGoogle Scholar
  40. 40.
    Dyer RK, White JM, Foster DJR, Bochner F, Menenlaou A, Somogyi A. The relationship between mood state and plasma methadone concentration in maintenance patients. J Clin Psychopharmacol. 2001;21(1):78–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Barry DT, Beitel M, Garnet B, Joshi D, Rosenblum A, Schottenfeld RS. Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. J Clin Psychiatry. 2009;70:1213–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manage. 2000;19:53–62.PubMedCrossRefGoogle Scholar
  43. 43.
    Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005;113:340–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289:2370–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction. 2008;103:1429–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Finnegan LP. Women, pregnancy and methadone. Heroin Addict Relat Clin Probl. 2000;2(1):1–8.Google Scholar
  47. 47.
    Suffett F, Brotman R. A comprehensive care programme for pregnant addicts: obstetrical, neonatal and child development outcomes. Int J Addict. 1984;19:199–219.Google Scholar
  48. 48.
    Sees K, Delucchi K, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence. JAMA. 2000;283:1303–10.PubMedCrossRefGoogle Scholar
  49. 49.
    Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf. 2000;22(3):179–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of MedicineBeth Israel Medical Center MMTPNew YorkUSA

Personalised recommendations